Phase II Study of Durvalumab in Combination With Lenalidomide in Relapsed/Refractory NK-T-cell Lymphoma

NCT03054532 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

22

Enrollment

OTHER

Sponsor class

Conditions

LYMPHOMA

Interventions

DRUG: Durvalumab
DRUG: Lenali

Sponsor

Singapore General Hospital

Collaborators

[object Object]